RAF1 and neoplasm: Vemurafenib was developed as a specific BRAFV600E inhibitor, and even though it binds and inhibits all RAF isoforms in vitro, vemurafenib only significantly limits cellular proliferation in cells and tumours harbouring BRAFV600E mutations.